ARRY-334543, EGFR/ErbB2 inhibitor; oral

DRUG5 trials

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer, Array BioPharma

Conditions

Advanced CancerPancreatic Cancer

Phase 1

A Study of ARRY-334543 in Patients With Advanced Cancer

CompletedNCT00278902

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Cancer

Start: 2006-01-31End: 2009-06-30Updated: 2020-10-14

A Study of ARRY-334543 in Patients With Advanced Cancer

CompletedNCT00637702

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Cancer

Start: 2008-02-29End: 2012-10-31Updated: 2020-10-08

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

CompletedNCT00710736

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Cancer

Start: 2008-06-30End: 2011-04-30Updated: 2020-10-06

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

CompletedNCT00833326

Array Biopharma, now a wholly owned subsidiary of PfizerAdvanced Cancer

Start: 2009-01-31End: 2010-07-31Updated: 2020-10-06

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

CompletedNCT00862524

Array BioPharmaAdvanced Cancer, Pancreatic Cancer

Start: 2009-03-31End: 2011-02-28Updated: 2012-10-04